360 related articles for article (PubMed ID: 22673139)
1. Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine to five years: a follow-up study.
Khatami A; Snape MD; Wysocki J; John TM; Westcar S; Mesaros N; Peddiraju K; Boutriau D; Yu LM; Pollard AJ
Pediatr Infect Dis J; 2012 Oct; 31(10):1069-73. PubMed ID: 22673139
[TBL] [Abstract][Full Text] [Related]
2. Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine.
Tejedor JC; Merino JM; Moro M; Navarro ML; Espín J; Omeñaca F; García-Sicilia J; Moreno-Pérez D; Ruiz-Contreras J; Centeno F; Barrio F; Cabanillas L; Muro M; Esporrin C; De Torres MJ; Caubet M; Boutriau D; Miller JM; Mesaros N
Pediatr Infect Dis J; 2012 Oct; 31(10):1074-7. PubMed ID: 22828645
[TBL] [Abstract][Full Text] [Related]
3. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
Vesikari T; Forstén A; Desole MG; Ferrera G; Caubet M; Mesaros N; Boutriau D
Pediatr Infect Dis J; 2013 May; 32(5):521-9. PubMed ID: 23190785
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L;
Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of a three-dose primary vaccination course of DTPa-IPV/Hib-MenC-TT followed by a 12-month Hib-MenC-TT booster in healthy infants.
Khatami A; Snape MD; Ohene-Kena B; Young K; Oeser C; Michaelis LJ; Macleod E; Smee H; Van Der Meeren O; Leyssen M; Caubet M; Yu LM; Heath PT; Faust SN; Finn A; Pollard AJ
Pediatr Infect Dis J; 2013 Jun; 32(6):675-81. PubMed ID: 23348809
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age.
Tejedor JC; Moro M; Merino JM; Gómez-Campderá JA; García-del-Rio M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Ruiz-Contreras J; Martin-Ancel A; Roca J; Boceta R; García-Corbeira P; Maechler G; Boutriau D;
Pediatr Infect Dis J; 2008 Jul; 27(7):579-88. PubMed ID: 18536619
[TBL] [Abstract][Full Text] [Related]
7. Three-year antibody persistence and safety after a single dose of combined haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in Hib-primed toddlers.
Booy R; Richmond P; Nolan T; McVernon J; Marshall H; Nissen M; Reynolds G; Ziegler JB; Stoney T; Heron L; Lambert S; Mesaros N; Peddiraju K; Miller JM
Pediatr Infect Dis J; 2013 Feb; 32(2):169-74. PubMed ID: 23080288
[TBL] [Abstract][Full Text] [Related]
8. Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Conjugate Vaccines.
Tejedor JC; Brzostek J; Konior R; Grunert D; Kolhe D; Baine Y; Van Der Wielen M
Clin Vaccine Immunol; 2016 Jul; 23(7):555-63. PubMed ID: 27145999
[TBL] [Abstract][Full Text] [Related]
9. A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial.
Pace D; Snape M; Westcar S; Oluwalana C; Yu LM; Begg N; Wysocki J; Czajka H; Maechler G; Boutriau D; Pollard AJ
Arch Dis Child; 2008 Nov; 93(11):963-70. PubMed ID: 18463125
[TBL] [Abstract][Full Text] [Related]
10. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months.
Díez-Domingo J; Cantarino MV; Torrentí JM; Sansano MI; Rosich AJ; Merino AH; de Miguel AG; González JB; Marcos MD;
Pediatr Infect Dis J; 2010 Feb; 29(2):148-52. PubMed ID: 19927040
[TBL] [Abstract][Full Text] [Related]
11. Combined Haemophilus Influenzae type B-Neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines.
Omeñaca F; Arístegui J; Tejedor JC; Moreno-Perez D; Ruiz-Contreras J; Merino JM; Muro Brussi M; Sánchez-Tamayo T; Castro Fernandez J; Cabanillas L; Peddiraju K; Mesaros N; Miller JM
Pediatr Infect Dis J; 2011 Nov; 30(11):e216-24. PubMed ID: 21747321
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
Marchant CD; Miller JM; Marshall GS; Blatter M; Aris E; Friedland LR; Boutriau D;
Pediatr Infect Dis J; 2010 Jan; 29(1):48-52. PubMed ID: 20035207
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and reactogenicity of Infanrix™ when co-administered with meningococcal MenACWY-TT conjugate vaccine in toddlers primed with MenHibrix™ and Pediarix™.
Leonardi M; Latiolais T; Sarpong K; Simon M; Twiggs J; Lei P; Rinderknecht S; Blatter M; Bianco V; Baine Y; Friedland LR; Baccarini C; Miller JM
Vaccine; 2015 Feb; 33(7):924-32. PubMed ID: 25305567
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine.
Schmitt HJ; Maechler G; Habermehl P; Knuf M; Saenger R; Begg N; Boutriau D
Clin Vaccine Immunol; 2007 Apr; 14(4):426-34. PubMed ID: 17287313
[TBL] [Abstract][Full Text] [Related]
15. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age.
Habermehl P; Leroux-Roels G; Sänger R; Mächler G; Boutriau D
Hum Vaccin; 2010 Aug; 6(8):640-51. PubMed ID: 20697200
[TBL] [Abstract][Full Text] [Related]
16. Five-year Antibody Persistence and Safety After a Single Dose of Combined Haemophilus influenzae Type B Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine in Haemophilus influenzae Type B-primed Toddlers.
Booy R; Nolan T; Reynolds G; Richmond P; Nissen M; Marshall H; Stoney T; Van Der Wielen M; Kolhe D; Miller JM
Pediatr Infect Dis J; 2015 Dec; 34(12):1379-84. PubMed ID: 26372451
[TBL] [Abstract][Full Text] [Related]
17. Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial.
Iro MA; Khatami A; Marshall AS; Pace D; Voysey M; McKenna J; Campbell D; Attard-Montalto S; Finn A; White C; Faust SN; Kent A; Heath PT; MacLeod E; Stanford E; Findlow H; Almond R; Bai X; Borrow R; Snape MD; Pollard AJ
Lancet Infect Dis; 2015 Feb; 15(2):172-80. PubMed ID: 25577661
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.
Pace D; Khatami A; McKenna J; Campbell D; Attard-Montalto S; Birks J; Voysey M; White C; Finn A; Macloed E; Faust SN; Kent AL; Heath PT; Borrow R; Snape MD; Pollard AJ
BMJ; 2015 Apr; 350():h1554. PubMed ID: 25832102
[TBL] [Abstract][Full Text] [Related]
19. Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy.
Pace D; Khatami A; Attard-Montalto S; Voysey M; Finn A; Faust SN; Heath PT; Borrow R; Snape MD; Pollard AJ
Vaccine; 2016 Dec; 34(50):6350-6357. PubMed ID: 28029540
[TBL] [Abstract][Full Text] [Related]
20. Antibody persistence for up to 5 years after a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) given at 12-15 months of age.
Marshall GS; Blatter M; Marchant C; Aris E; Mesaros N; Miller JM
Pediatr Infect Dis J; 2013 Jun; 32(6):662-8. PubMed ID: 23340564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]